Therapeutic Cyclodextrins
A few years ago the founders of Okklo Life Sciences were actively involved in the development of a very innovative new application of modified cyclodextrins. Instead of using a CD to deliver a drug, a CD molecule was designed in such a way that it was able to selectively scavenge a specific drug from the blood. Since CDs are cleared rapidly via renal excretion, the targeted drug will be eliminated together with the CD from the body very rapidly.
This first therapeutically active CD (Sugammadex, Bridion®) was specifically designed to scavenge certain muscle relaxants used in surgery, and is marketed in more than 60 countries.